SAN FRANCISCO, June 3, 2025 — Vector AIS, the modern fund administrator purpose-built for closed-end alternative investment funds, is excited to announce that John Spiridis will join the firm as Senior Vice President, Enterprise Growth & Services, beginning in early June.

John brings over two decades of experience spanning fund administration and private markets operations, having held senior roles at industry-leading firms including Credit Suisse, Citco, BNY Mellon, TPG, and most recently Man Varagon. With deep expertise across both the GP and fund administrator perspectives, John is uniquely positioned to help guide Vector’s next phase of growth and platform evolution.

As Vector continues expanding its footprint across private equity and adjacent private market strategies, John’s appointment underscores the firm’s commitment to building strategic infrastructure and capabilities that scale with client needs. In his new role, John will lead efforts to strengthen Vector’s private equity service offering, refine go-to-market strategies, and support cross-functional growth initiatives across product, delivery, and business development.

“We’re thrilled to welcome John to the team,” said Molly Yakubian, CEO. “His background, values, and vision align closely with where we’re headed as a company. John’s experience on both sides of the private markets ecosystem gives him an exceptional ability to see around corners and ensure we scale intentionally, sustainably, and always with the client at the center.”

John’s mandate will span asset classes, with an initial focus on private equity. He will also play a key role in shaping the roadmap for Valence, Vector’s proprietary technology platform, and in fostering strategic partnerships, referral relationships, and industry visibility through thought leadership.

Known for his collaborative approach and emphasis on team culture, John is already resonating with Vector’s values and mission. “From the outset, it’s been clear that John brings not just exceptional experience, but also the energy, warmth, and curiosity that make Vector special,” said Molly.

To learn more about John Spiridis, visit his LinkedIn profile.

Contact Information

[email protected]

www.vectorais.com

https://www.linkedin.com/company/vector-ais/

SOURCE Vector AIS

SOMERVILLE, Mass., June 3, 2025 — Matterworks, Inc., the category-defining pioneer unlocking unstructured molecular data for predictive biology, today announces new Series A financing. The round was led by Lewis & Clark Partners and OMX Ventures, joined by Pillar VC, Germin8 Ventures, Intermountain Ventures, and Tarsadia, among others. The Company will use its Series A proceeds to grow its model as a service (MaaS) business and expand its machine learning and scientific operations.

Jack Geremia, Matterworks CEO and Co-Founder, “I am delighted to partner with Lewis & Clark and welcome Carolyn Fritz to the Company’s Board of Directors as we accelerate machine intelligence innovations that tackle the unsustainable cost of life science R&D.”

Carolyn Fritz, Operating Partner at Lewis & Clark Partners, “In collaboration with its customers, Matterworks has repeatedly demonstrated its AI platform provides a step change reduction in the cost and throughput of mass spec quantitation.  We are excited to partner with this team in accelerating commercialization of their transformational technology.”

Craig Asher, Managing Director from OMX Ventures, “Matterworks is leveraging AI to unlock a new data layer for biology by making mass spectrometry accessible to all biologists. It’s a shift as transformative as single-cell sequencing and we are thrilled to support this exceptional team.”

About Matterworks
Matterworks’ Large Spectral Models (LSMs) productize self-supervised machine intelligence for direct machine interpretation of molecular-omic data. Pyxis^TM, released in 2024, is the first generative AI for complete untargeted molecular annotation, unlocking new data modalities for understanding and predicting complex biological outcomes. 

About Lewis & Clark Partners
Lewis & Clark Partners is a St. Louis-based group of experienced investment professionals passionate about investing in companies at the forefront of science, health, food, and agriculture innovation. We invest in growth-stage companies poised to scale nationally or globally. As founders, operators, investors, and scientists, our seasoned investment team brings deep sector expertise and insight to every investment.

About OMX Ventures
OMX Ventures is a venture capital firm focused on investing in a new era of bioengineering and its application for better tools, medicines, foods, industrial products, and more. We specialize in early­ stage investments at the intersection of biology, big data, and Al, with a focus on therapeutics, bio tools, diagnostics, and synthetic biology platforms.

SOURCE Matterworks

Enables Agenus to accelerate development of its lead BOT/BAL programme and strategically expand into high-unmet need indications and earlier lines of treatment.

The investment underscores Zynext Ventures‘ commitment to advancing innovation in critical therapeutic areas.

PENNINGTON, N.J., June 3, 2025 — Zynext Ventures USA LLC (Zynext), the venture capital arm of Zydus Lifesciences (Zydus), today announced its investment in Agenus Inc., a leading US-based immuno-oncology company developing next–generation therapeutics for high-unmet need cancers.

Agenus’ lead programme comprising Botensilimab (BOT) and Balstilimab (BAL), is a next-generation immunotherapy platform designed to strengthen and sustain the immune system’s response against tumour cells. Currently in advanced clinical trials, BOT/BAL have demonstrated significant clinical activity across nine cancer types in more than 1,200 patients, including both late-stage and neoadjuvant settings.

“Our investment in Agenus aligns perfectly with our vision to advance life-changing therapies and offer novel solutions anchored on science, innovation and health to empower patients,” said Dr. Sharvil Patel, Managing Director of Zydus Lifesciences. “Our extensive global partner network will also play a key role in supporting Agenus’ entry into new indications and geographies, allowing these innovative therapies to reach more patients, faster. This collaboration will help propel Agenus’ programmes and unlock their full potential.”

In addition to capital, Zynext Ventures will bring deep expertise in data analytics and access to a broad global network of biotech, regulatory, and clinical partners. This synergistic approach aims to unlock new avenues for Agenus, enabling the company to broaden the application of its BOT/BAL programme into earlier lines of treatment and address a wider spectrum of cancers with significant unmet medical needs.

Dr. Garo Armen, Chairman and CEO of Agenus, said, “We are delighted to partner with Zynext Ventures in a truly synergistic relationship. BOT/BAL’s remarkable results across nine distinct cancers, in both late-stage and neoadjuvant settings, inspire us to push the boundaries of what is possible in oncology. Zydus’ commercial reach and expertise make them an ideal partner to accelerate the delivery of this potentially transformative therapy.”

About Zynext Ventures

Zynext Ventures is the investment arm of Zydus Lifesciences. The venture capital firm focuses on identifying and investing in promising early-stage and growth-stage companies in the healthcare sector. Zynext Ventures provides financial support, strategic guidance, and industry expertise to its portfolio companies, helping them achieve their full potential and make a meaningful impact on the lives of patients.

For more details visit: www.zynextventures.com

LinkedIn: Zynext Ventures

Twitter: @ZynextVentures

About Zydus

Zydus Lifesciences Ltd. with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs 27,000 people worldwide, including 1,400 scientists engaged in R & D, and is driven by its mission to unlock new possibilities in lifesciences through quality healthcare solutions that impact lives. The group aspires to transform lives through path-breaking discoveries. Over the last decade, Zydus has introduced several innovative, first-in-class products in the market for treating unmet healthcare needs with vaccines, therapeutics, biologicals and biosimilars.

For more details visit: www.zyduslife.com.

LinkedIn: @Zydusuniverse

Instagram: @ZydusUniverse

About Agenus

Agenus Inc. is a clinical-stage immuno-oncology company committed to developing immune therapies that effectively combat cancer. Leveraging proprietary scientific platforms, the company’s pipeline includes multiple checkpoint antibody candidates, vaccines, and cell therapies. Headquartered in Lexington, MA, Agenus operates globally, driving innovations to bring better cancer treatments to patients.

For more details visit: www.agenusbio.com.

Forward-Looking Statements

This press release contains forward-looking statements regarding the planned collaboration, the development and commercialization of BOT/BAL, and anticipated timelines. Actual results may differ due to various risks and uncertainties, including regulatory approvals and other factors. Readers are encouraged to review each company’s public filings for additional information regarding potential risks and timelines.

Logo: https://mma.prnewswire.com/media/2442038/5213236/Zynext_Ventures_Logo.jpg

SOURCE Zynext Ventures

Success of the home-based care model caught the eye of notable investors, including Deerfield Management and GV (Google Ventures). 

NEW YORK, June 3, 2025 — myLaurel, a rapidly growing healthcare company delivering home-based acute and transitional care, today announced it raised additional capital and held an initial closing of $12 million from existing investors. The round is led by Deerfield Management and GV, with participation from Emerson Collective, Pinta Partners, Ochsner Health, and management.

This funding follows a record-breaking 2024 and continued growth in the first quarter of 2025, marked by a 4x year-over-year increase in new patient volume and revenue. myLaurel’s signature Acute Care at Home program continues to show strong clinical and financial outcomes for its hospital partners, most notably through its partnership with Ochsner. The new capital will enable the company to further expand with Ochsner and accelerate growth with new health system clients, focusing on scaling Acute Care at Home in both existing and new markets.

As the U.S. population continues to age, the demand for scalable, high-quality care outside the traditional hospital is growing rapidly. A recent report in JAMA warns that the country could face a “dangerous threshold” of hospital bed shortages by 2032, driven in large part by an aging population with increasingly complex medical needs. myLaurel’s model directly addresses this challenge by enabling hospitals to deliver high-acuity care in patients’ homes, improving outcomes while reducing the strain on facility throughput and capacity. 

“Our momentum reflects both the urgency of the need and the strength of our care model solution,” said Juan Vallarino, CEO of myLaurel. “In partnership with systems like Ochsner, we demonstrate that high-acuity, home-based care can provide an exceptional patient experience, reduce costs, and meaningfully extend hospital capacity. This funding round validates our vision and positions us to serve more patients with greater efficiency and impact.”

In 2024, myLaurel and Ochsner Health jointly developed the Acute Care at Home model, which has since outperformed expectations in clinical and operational metrics. The partnership has become a benchmark for how health systems can modernize care delivery for complex, frail, and elderly patients outside of traditional hospital walls.

“myLaurel is pioneering a scalable care model that addresses one of the most pressing challenges in healthcare — how to safely and effectively care for complex patients outside the hospital,” said Moses Adubi, Principal at Deerfield. “We believe myLaurel is well-positioned to lead a transformation in acute care and deliver benefits across the continuum of care.”

As the healthcare industry increasingly embraces home-based care for medically complex populations, myLaurel delivers the best of both worlds: an enhanced patient experience and improved hospital efficiency. This combination has made myLaurel a strategic partner for health systems, payers, and patients alike.

About myLaurel
myLaurel was founded on the belief that a portion of today’s hospital care can—and should—be delivered in the comfort of home.  As a tech-enabled medical group, we provide on-demand acute and transitional care to frail, elderly, or medically complex patients at home—helping them avoid the traditional care path of ambulance, ER, hospital admission, and nursing facility.  

Health systems, provider groups, and payers partner with us to reduce avoidable utilization, improve readmission rates, accelerate discharges, and enhance patient experience—all while maintaining the highest standards of care and safety. We stand behind our outcomes with our partners, putting our fees at risk to demonstrate our commitment and confidence in delivering results.  

Headquartered in New York, myLaurel delivers hands-on clinical care guided by remote physicians and supported by advanced technology, diagnostics, and therapies. The result: 33% lower ED utilization, 49% fewer readmissions, 3,000+ bed days saved per hospital annually – enabling over 640 additional acute inpatient admissions –  and a patient Net Promoter Score of 96. Learn more at mylaurelhealth.com.

About Deerfield Management

Deerfield is an investment management firm committed to advancing healthcare through investment, information, and philanthropy. The Firm works across the healthcare ecosystem to connect people, capital, ideas, and technology in bold, collaborative, and inclusive ways. For more information, please visit www.deerfield.com.

About GV
GV supports innovative founders across multiple stages and sectors, from artificial intelligence and life sciences to consumer platforms, enterprise software, and frontier technology.

Launched as Google Ventures in 2009, GV oversees more than $10 billion in assets under management. Our operating partners support founding teams at every stage of company-building across executive talent, design, communications, and marketing. GV is a non-strategic venture capital firm that invests independently from its sole limited partner, Alphabet. We connect startups with Google and Alphabet companies, providing unique access to the world’s best technology and talent.

GV has 400 active portfolio companies spanning North America, Europe, and Israel. Our portfolio includes Lightmatter, Stripe, Treeline Biosciences, Vercel, and Wonder, with notable exits including Uber, Nest, Slack, GitLab, Duo Security, Flatiron Health, Lemonade, and One Medical. The firm is headquartered in the San Francisco Bay Area, with offices in Cambridge, New York, and London. For more information, please visit gv.com.

For more information contact:
[email protected]

SOURCE myLaurel

PLEASANTON, Calif., June 3, 2025 — Deep Sentinel, the leader in proactive AI-powered security, today announced it has raised an oversubscribed $15 million in Series B funding led by Egis Capital Partners. The round also received continued support from existing backers such as Intel Capital, Shasta Ventures, UP2398, and Slow Launch Fund. Deep Sentinel has doubled its sales bookings year over year and continues to outpace traditional players in a legacy industry where most companies grow at 20 to 30 percent annually.

The latest investment will support Deep Sentinel’s rapid expansion, continued development of its proprietary AI models and scaling of its Bring Your Own Camera (BYOC) third-party camera integration program, which now accounts for nearly half of all sales. The company is also focused on growing its national footprint across commercial and residential sectors.

“This funding marks a new chapter in our mission to redefine what proactive security looks like,” said David Selinger, founder and CEO of Deep Sentinel. “We’re not just adding more cameras or software features. We’re transforming how people experience safety, with a platform that delivers real-time intervention at the highest standard in the industry.”

The BYOC program is especially important in this vision for Selinger: “With support for plug-and-play integration with key brands such as Digital Watchdog, Axis, Uniview, Hikvision, Luma/SnapOne, we are able to reach a growing market segment – businesses who want to improve the capabilities of existing hardware instead of ‘Rip-and-Replace’, as well as their partners.”

Deep Sentinel offers an integrated approach to crime prevention, combining artificial intelligence with live human guards. Its proprietary platform monitors video feeds in real time, and trained guards intervene within seconds when suspicious behavior is detected. The platform can be integrated with existing camera hardware, helping businesses avoid costly equipment upgrades and reduce upfront investment.

The addition of Egis brings more than just capital to the table. With a deep track record in physical security and technology, the firm brings strategic insight and operational experience to support Deep Sentinel’s growth and scaling.

“Egis Capital Partners is thrilled to lead Deep Sentinel’s Series B financing, fueling the continued growth of a leader in next-generation, AI-enabled proactive security solutions. Since 2008, Egis has been a dedicated investor in the security and safety industry, with Deep Sentinel representing our fifth investment in remote video monitoring across our three funds. We are excited to back Deep Sentinel, led by David Selinger, and support Deep Sentinel’s vision of making every family, business, and community safe and secure,” said Robert Chefitz, Founder and Managing Partner at Egis Capital Partners. 

About Deep Sentinel

Deep Sentinel is revolutionizing physical security for businesses and homes as the only system that stops crime before it happens. Our patented AI system adds real-time video monitoring and live human guards to passive security cameras, turning almost any security system into part of Deep Sentinel’s exclusive crime-stopping network — and preventing thousands of crimes each month.

Trusted by hundreds of security integrators and thousands of businesses across the U.S., Deep Sentinel’s proprietary AI constantly monitors from the perimeter to the secure interior of properties to instantly detect suspicious activity and dispatch live guards. These highly-trained remote guards (“Live Sentinels”) intervene through two-way audio and escalate to law enforcement as needed.

Deep Sentinel’s AI-powered live guard service integrates effortlessly with a range of camera systems — whether existing third-party cameras or Deep Sentinel’s own. This gives businesses and security integrators a plug-and-play upgrade path that complements their current security and analytics tools. For more information, visit www.deepsentinel.com.

Media Contact: 

Ksenia Kulik 

Interdependence Public Relations    

[email protected]

(919)-349-3786  

SOURCE Deep Sentinel

New fund will continue to focus on scaling breakthroughs in Robotics and Physical AI

BOSTON, June 3, 2025 — Boston-based Cybernetix Ventures, a leading US early-stage venture capital firm investing in robotics, automation and physical AI technology companies, today announces its second fund. Leveraging its longstanding leadership in robotics, and unparalleled deep and wide network in robotics the firm is launching this fund to fuel the next generation of breakthrough solutions for industries where innovation matters most. This fund will build on the success of the firm’s current fund 23 investments in companies across the US and Europe developing solutions for critical vertical markets, including manufacturing, logistics, construction, agriculture, climate and healthcare. Cybernetix is led by robotics experts Fady Saad and Mark Martin, who have 50 years of combined robotics technologies, operations and investing experience. 

“We’ve been evangelizing the inevitable potential of intelligent machines for over a decade, and the emergence of physical AI has finally made once-theoretical use cases commercially viable. Robotics is no longer a fringe interest; it’s a distinct, nuanced asset class with unique dynamics. In today’s venture environment, investors are increasingly paying higher prices for early-stage exposure, often without the operational insight to manage the associated risk,” said General Partner Fady Saad. “At Cybernetix, we’re purpose-built for this moment. Our deep sector expertise, active corporate partnerships, and intimate understanding of the ecosystem allow us to underwrite risk more intelligently and unlock real value where others simply speculate.”

With approximately 1,200 deal flow opportunities per year, Cybernetix Ventures has already built an investment portfolio of leading early-stage robotics and physical AI companies covering their target technology and market sectors. Among them are Raise Robotics, which helps workers with challenging tasks on construction sites, making jobs safer and improving productivity, Rugged Robotics, which uses automation and robotics to automate facilities, such as warehouses, data centers, and construction sites, and Airworks, which leverages geospatial surveying for large scale infrastructure. Cybernetix has seen significant markups in valuations as many of these companies have moved through their funding rounds. According to Grandview Research, the global AI in robotics market was valued at approximately $12.77 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 38.5%, reaching around $124.77 billion by 2030.

“Cybernetix was designed from the ground up to serve one purpose: backing the world’s most promising robotics startups with the insight, capital, and network they need to scale. We’ve built one of the most targeted and efficient investment models in the robotics sector today,” said General Partner Mark Martin. “If you believe in the long-term power of the robotics megatrend, and you understand that the highest returns come from getting in early, Cybernetix is the firm to watch. Our conviction is deep, our lens is precise, and our track record speaks to the strength of this category when approached with discipline and domain focus.”

The Cybernetix expertise is also bolstered by key advisors from iRobot, Kiva/Amazon Robotics, Flagship Ventures, Locus Robotics, Tufts University, and Cummings Foundation. This new fund will expand into agriculture and climate, which is why the firm is adding Mark DeSantis, an expert in agriculture robotics, to its impressive advisory roster. 

The team prides itself in being leaders in the ecosystem and also launched Robotics Invest, entering its third year as an annual high-quality, exclusive masterclass attended by 300 robotics leaders each June in Boston. Scheduled speakers hail from companies such as: Clearpath Robotics/Rockwell Automation, Dexterity, Wall Street Journal, Re:Build Manufacturing, and investment banking leaders including JP Morgan and Evercore, and more. Panel discussions include “The 5 W’s of Investing in Robotics (including Humanoids)” and “Why Investing in Robotics is Different from SaaS and Deep Tech.”

About Cybernetix Ventures
Cybernetix Ventures is a venture capital firm investing in early-stage robotics, automation, and physical AI startups. Headquartered in Boston, a growing epicenter for robotics innovation, Cybernetix connects its portfolio to the national and global robotics ecosystems, bringing unparalleled expertise to companies poised to make major impacts in sectors including advanced manufacturing, logistics/warehousing, agriculture, engineering and construction and healthcare/medical devices. For more information, please visit www.cybernetix.vc. Cybernetix recently debuted their Robotics Startup Playbook, showing founders and investors how to successfully navigate this very unique investment class. See the Playbook here.

SOURCE Cybernetix

Canapi Ventures leads investment round to accelerate FISPAN’s growth

VANCOUVER, BC, June 3, 2025 – FISPAN, the industry leader in embedded ERP banking solutions, announced today that it has closed $30 million USD in Series B funding led by fintech and enterprise software investment firm Canapi Ventures. This new capital will accelerate FISPAN’s mission of seamlessly integrating banking services directly into businesses’ enterprise resource planning (ERP) systems and accounting software.

Bridging the Gap Between Banks and Businesses

For many years banks have invested in host-to-host and API platforms, enabling large enterprises to reap the productivity benefits of connecting to their financial institutions directly. FISPAN packages those connectivity capabilities and enables banks to distribute their treasury products to mid-market and smaller businesses via an easy to install, out-of-the-box, in-ERP plugin.

Trusted by the world’s largest banks and nearly 5,000 businesses across North America, FISPAN enables banks to deliver modern, integrated client experiences by embedding key financial and banking capabilities directly into their existing ERP system or accounting software. For businesses, this means:

• Centralized Financial Workflows: Integrating financial transactions and operational workflows into a single system, eliminating inefficiencies and disconnected processes
• Automated Processes: Built-in automation streamlines routine tasks like payment initiation and approval processes – saving time and lowering costs
• Fewer Manual Errors: Direct ERP integrations minimize manual uploads and data entry, improving accuracy and minimizing operational risk

Through seamless API integration with systems like Oracle NetSuite, Sage Intacct, and Microsoft Dynamics 365 Business Central, banks can offer contextual solutions that streamline payables, cash management, and reconciliation.

“This Series B funding is a pivotal moment for FISPAN, empowering us to significantly scale our innovation and market reach,” said Lisa Shields, CEO & Founder at FISPAN. “Canapi quickly distinguished themselves through their understanding of the embedded ERP banking landscape and our unique opportunity within it. With an LP network of over 75 financial institutions—and partners with banktech operating expertise — Canapi is a natural partner for our next chapter. We’re excited to work with Canapi to help more treasury teams optimize their operations.”

Driving the Next Phase of FISPAN’s Expansion

In conjunction with the investment, Tom Davis from Canapi Ventures will join FISPAN’s board of directors. This new capital will fuel several key growth opportunities:

• Accelerated Product Development: Deepen AI capabilities, expand ERP and accounting system integrations, and enhance platform capabilities to support full-stack treasury solutions
• Expanded Market Reach: Scale go-to-market efforts in key regions and significantly grow banking and channel partner networks
• Strategic Talent Acquisition: Expand FISPAN’s world-class team with top-tier talent to accelerate product leadership and customer experience

“FISPAN is at the forefront of a fundamental shift in how businesses interact with their banks,” said Tom Davis, General Partner at Canapi. “Their proven ability to deliver highly sought-after embedded finance solutions positions them for tremendous growth. Our investment reflects our confidence in their visionary team and their capacity to build a leading platform that drives efficiency and value for both financial institutions and their corporate clients.”

About FISPAN

FISPAN is a leading fintech company that seamlessly integrates banks with their clients’ enterprise resource planning (ERP) and accounting systems. Founded in 2016, FISPAN provides innovative ERP banking solutions that eliminate the complexities and frustrations of traditional banking services. By embedding banking services directly into ERP and accounting software, FISPAN streamlines financial workflows, reduces costs, minimizes manual errors, and enhances efficiency for businesses of all sizes. For more information, head to www.fispan.com.

About Canapi Ventures

Canapi is a multi-stage venture capital firm investing in fintech and enterprise software. Backed by the Canapi Alliance – a network of over 70 of the leading financial institutions across the United States – Canapi brings unmatched sector experience and best-in-class knowledge, connections, and credibility to founders. For more information, visit www.canapi.com.

SOURCE FISPAN

Backed by leading institutional Limited Partners, Ventures Fund III underscores the need for thematically aligned investors in today’s market

CHICAGO, June 3, 2025 — Energize Capital, a leading multi-stage investor in climate solutions, today announced the close of its Ventures Fund III (“Ventures III”) totaling $430 million in capital commitments to the fund and its related vehicles. The firm’s fifth institutional fund and third of its Ventures strategy, Ventures III will deploy into earlier-stage companies focused on scaling energy and industrial transformation through digital and software-enabled solutions. This latest raise brings Energize’s total assets under management to over $1.8 billion and will empower the specialist firm to continue leveraging its team’s decades of expertise in climate technology to support entrepreneurs through both financial capital and extensive operational and commercialization support.

Today’s economy is undergoing a profound transformation, placing new demands on capital partners to navigate emerging complexity and create value. Technologies like AI are redefining industrial processes, driving innovation, efficiency, and scalability. At the same time, the reshoring of manufacturing, evolving global supply chains, and the accelerating energy transition are reshaping critical infrastructure. These shifts are creating significant opportunities in areas such as grid interconnection, next-generation manufacturing, and the circular economy—all of which increasingly rely on digital tools to manage complexity and unlock value. With a thesis grounded in digital-first climate solutions and a track record of scaling companies in these evolving sectors, Energize is well-positioned to be a critical partner in this next chapter.

“Now on our third ventures fund, the Energize team has been investing in climate technologies and solutions across several cycles, and we’ve experienced firsthand how this space has evolved in both market size and complexity,” said John Tough, managing partner at Energize Capital. “Today more than ever, operators need specialist investors with deep domain expertise and operational know-how to help them scale their solutions and achieve enduring growth. We are excited to back the next generation of entrepreneurs and are honored to be supported by a group of world-class Limited Partners who align with our mission of investing in climate solutions with ambition.”

Energize’s Ventures Fund III is backed by LPs that represent leading institutional, corporate strategic, family office and impact investors. New LPs in the fund include Första AP-Fonden (AP1), Capricorn, Reference Capital, Keeling Capital, Keysight Technologies, WEX Venture Capital, and several other international pensions. Among returning investors are GE Vernova, CDPQ, Builders Vision, UBS, WEC, and others.

“As an investor committed to accelerating the energy transition, Builders Vision values Energize’s deep industry insights and proven approach to scaling energy transition SaaS businesses,” said Scott Gerdes, director of private investments at Builders Vision. “The close of Ventures Fund III is an opportunity for Energize to further enhance its in-depth research, valuable industry connections, and hands-on team, all of which are crucial for driving broader market adoption. By collaborating with forward-thinking companies and leveraging cutting-edge technology, Energize is fueling growth and contributing to the creation of a cleaner, more resilient energy ecosystem.”¹

The fund will back asset-light climate solutions, with a particular focus on companies operating in the industrial digitization, next generation infrastructure and energy transition sectors. To date, Energize has deployed capital from Ventures III into several investments, including Tyba, a battery software optimization platform; Archive, a technology solution for brands to launch and scale profitable resale businesses; and Nira, a software platform that supports grid interconnection for energy developers.

About Energize Capital
Energize Capital is a leading investor in climate solutions. Founded in 2016 and based in Chicago, Energize seeks to scale sustainable innovation by partnering with the builders and operators shaping the future. To date, Energize has funded 36 companies and deployed more than $920 million through its Venture and Endurance strategies. Founded in partnership with Invenergy, the firm is backed by strategic, institutional, and impact LPs including Första AP-Fonden (AP1), GE Vernova, Capricorn, CDPQ, Builders Vision, UBS, WEC, Reference Capital, Keeling Capital, Keysight Technologies, WEX Venture Capital, and more. For more information on Energize, please visit www.energizecap.com.

Media Contact
Robiny Jamerson, Energize Marketing & Communications, [email protected] 

¹ No compensation was provided in exchange for this testimonial

SOURCE Energize Capital

New funding will support the company’s rapid growth trajectory and efforts to transform pharmaceutical supply chains with its advanced biomanufacturing platform

MENLO PARK, Calif., June 3, 2025 — Antheia, the pharmaceutical ingredient manufacturer transforming essential medicine supply chains, today announced it has raised $56 million in Series C financing. The new financing will be used to expand commercialization of Antheia’s first product, thebaine, and launch additional products from the company’s pipeline of 70+ biosynthetic pharmaceutical ingredients, which spans seven therapeutic areas and prioritizes essential medicines in or at risk of shortage. Additionally, the funding will allow Antheia to unlock its U.S. manufacturing operations to meet domestic demand and begin new strategic innovation programs in Singapore, while expanding into the broader Asia region.

“Our industry-first biosynthetic product offerings are disrupting the market by addressing major supply chain issues and are quickly cementing Antheia’s position as a leading industry innovator,” said Dr. Christina Smolke, CEO and co-founder of Antheia. “In collaboration with our investors, customers, and manufacturing partners, we are enabling widespread access to critical medicines with our world-leading biosynthesis technology. We are immensely grateful to these partners that share our vision for the next generation of pharma, and we look forward to achieving more industry-first milestones with today’s financing.”

Drug shortages remain a persistent problem plaguing nations worldwide and are exacerbated by supply chain disruptions, climate crises, and shifting geopolitics. Antheia’s biomanufacturing platform is ushering in the next era of efficient, agile, and distributed pharmaceutical manufacturing that can be implemented when and where needed to meet the demands of 21^st century healthcare systems.

The Series C financing was led by Global Health Investment Corporation (GHIC), a U.S.-based investment firm with an established history of supporting innovation in global health and health security and EDBI, operating under SG Growth Capital, the investment platform of the Singapore Economic Development Board (EDB) and Enterprise Singapore. Additional new investors in this round include ATHOS KG and Federov, with participation from existing investors, including Viking Global Investors, Sherpalo Ventures, S-Cubed Capital, In-Q-Tel (IQT), and Civilization Ventures.

“Global pharmaceutical supply chains are complex and increasingly vulnerable to critical drug shortages – an urgent health security challenge,” said Joseph Lee, Principal at GHIC. “Antheia’s biosynthesis platform offers a transformative and elegant solution, enabling more efficient, scalable, and reliable production of KSMs and APIs. We are excited to support Antheia’s next phase of growth and to partner in building a more resilient future for global biomanufacturing.”

“Antheia’s pioneering biosynthesis platform transforms essential medicine supply chains by addressing critical bottlenecks. As Singapore strengthens its position as Asia’s biotech hub, EDBI is proud to partner with Antheia to advance bio-based innovation. We see significant opportunities for Antheia to expand its biomanufacturing capabilities and applications through collaborations with Singapore’s vibrant scientific ecosystem – including A*STAR, Singapore’s lead public sector R&D agency – creating valuable synergies for future growth across Asia,” said Paul Ng, Chief Executive Officer of EDBI.

Today’s news comes on the heels of several major milestones, including Antheia’s first commercial delivery of thebaine – the key ingredient used to produce Narcan – and two U.S. government project agreements valued up to a combined $23 million to onshore pharmaceutical supply chains. Antheia’s strong commercial momentum and the broader industry response underscore the company’s vital role in modernizing global pharmaceutical supply chains and realizing biomanufacturing’s potential to solve the world’s most pressing problems.

About Antheia
Antheia is the next-generation pharmaceutical ingredient producer with a mission to end drug shortages. Using advanced biosynthesis and fermentation technology, Antheia’s biomanufacturing platform enables rapid, efficient, agile, and on-demand production of key starting materials (KSMs) and active pharmaceutical ingredients (APIs) that are critical to public health. This highly flexible approach supports the needs of a growing society and improves global access to essential medicines. Founded in 2015, Antheia has grown into a commercial stage company with its first product to market, an active customer pipeline, and near-term product launches. For more information on how Antheia is transforming pharmaceutical supply chains, visit www.antheia.bio.

MEDIA CONTACT:
Mission North for Antheia
[email protected]

SOURCE Antheia